The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema
Open accessAbstract
Dipeptidyl peptidase-IV (DPP-IV) inhibitors decrease degradation of the incretins. DPP-IV inhibitors also decrease degradation of peptides, such as substance P, that may be involved in the pathogenesis of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema. This study tested the hypothesis that DPP-IV inhibition affects risk of clinical angioedema, by comparing the incidence of angioedema in patients treated with the DPP-IV inhibitor vildagliptin versus those treated with comparator in Phase III randomized clinical trials. Prospectively defined angioedema-related events were adjudicated in a blinded fashion by an internal medicine adjudication committee and expert reviewer. Concurrent ACE inhibitor or angiotensin receptor blocker exposure was ascertained from case report forms. Study drug exposure was ascertained from unblinded data from phase III studies. Odds ratios and 95% confidence intervals comparing angioedema risk in vildagliptin-treated and comparator-treated patients were calculated for the overall population and for patients taking ACE inhibitors or angiotensin receptor blockers, using both an analysis of pooled data and a meta-analysis (Peto method). Overall, there was no association between vildagliptin use and angioedema. Among individuals taking an ACE inhibitor, however, vildagliptin use was associated with an increased risk of angioedema (14 confirmed cases among 2754 vildagliptin users versus 1 case among 1819 comparator users: odds ratio 4.57 [95% confidence interval 1.57 to 13.28]) in the meta-analysis. Vildagliptin use may be associated with increased risk of angioedema among patients taking ACE inhibitors, although absolute risk is small. Physicians confronted with angioedema in a patient taking an ACE inhibitor and DPP-IV inhibitor should consider this possible drug–drug interaction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Lambeir, A.-M., Durinx, C., Scharpé, S., & De Meester, I. (2003) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/713609354 · Cited by 955
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Russell Localio, A. (2007) · Statistics in Medicine · doi:10.1002/sim.2528 · Cited by 938
The Kallikrein-Kinin System: Current and Future Pharmacological Targets
Moreau, M. E., Garbacki, N., Molinaro, G., Brown, N. J., Marceau, F., & Adam, A. (2005) · Journal of Pharmacological Sciences · doi:10.1254/jphs.srj05001x · Cited by 457
Self-citationBrown, N. J., Ray, W. A., Snowden, M., & Griffin, M. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90161-7 · Cited by 313
Self-citationIncidence and Characteristics of Angioedema Associated With Enalapril
Kostis, J. B., Kim, H. J., Rusnak, J., Casale, T., Kaplan, A., Corren, J., & Levy, E. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.14.1637 · Cited by 291
Angioedema Incidence in US Veterans Initiating Angiotensin-Converting Enzyme Inhibitors
Miller, D. R., Oliveria, S. A., Berlowitz, D. R., Fincke, B. G., Stang, P., & Lillienfeld, D. E. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.110270 · Cited by 238
Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema
Byrd, J. B., Touzin, K., Sile, S., Gainer, J. V., Yu, C., Nadeau, J., Adam, A., & Brown, N. J. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.096552 · Cited by 147
Self-citation
Research works printed but not linked: 22
- 10.1210/jc.2004-2460 · DOI · Paper page
- 10.1055/s-2006-944546 · DOI · Paper page
- 10.1007/s00125-006-0416-z · DOI · Paper page
- 10.1210/jc.2006-1009 · DOI · Paper page
- 10.2337/diacare.28.8.1936 · DOI · Paper page
- 10.1111/j.1463-1326.2007.00744.x · DOI · Paper page
- 10.1161/hyp.31.6.1299 · doi:10.1161/hyp.31.6.1299
- 10.1161/hyp.39.2.460 · doi:10.1161/hyp.39.2.460
- 10.1001/jama.298.2.194 · DOI · Paper page
- 10.1016/S1047-2797(97)00084-7 · DOI
- 10.1016/j.clinthera.2006.10.007 · DOI · Paper page
- 10.1186/1472-6823-8-14 · DOI
- 10.1016/j.iac.2006.08.001 · DOI · Paper page
- 10.1056/NEJM198305053081802 · DOI · Paper page
- Ahmad S, Wang L, Ward PE. Dipeptidyl(amino)peptidas IV and aminopeptidase M metabolize circulating substance P in vivo. J Pharmacol Exp Ther. 1992; 260: 1257–1261. · DOI
- 10.1124/jpet.103.064105 · DOI · Paper page
- 10.1001/jama.1988.03410070095035 · DOI · Paper page
- 10.1111/j.1524-6175.2003.01924.x · DOI
- 10.1016/j.amjhyper.2003.09.014 · DOI · Paper page
- 10.1038/nm0897-904 · DOI · Paper page
- 10.2337/diacare.21.4.597 · DOI · Paper page
- 10.1016/S0140-6736(00)02596-4 · DOI · Paper page
Cited by
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Oparil, S., Acelajado, M. C., Bakris, G. L., Berlowitz, D. R., Cífková, R., Dominiczak, A. F., Grassi, G., Jordan, J., Poulter, N. R., Rodgers, A., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.14 · Cited by 1,167
Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations
Singh, A. K., Gupta, R., Ghosh, A., & Misra, A. (2020) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2020.04.004 · Cited by 893
Williams-Herman, D., Engel, S. S., Round, E., Johnson, J., Golm, G. T., Guo, H., Musser, B. J., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2010) · BMC Endocrine Disorders · doi:10.1186/1472-6823-10-7 · Cited by 258
Liu, L., Liu, J., Wong, W. T., Tian, X. Y., Lau, C. W., Wang, Y.-X., Xu, G., Pu, Y., Zhu, Z., Xu, A., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.195115 · Cited by 179
Metadata
- Authors
- Brown, N. J., Byiers, S., Carr, D., Maldonado, M., & Warner, B. A.
- Venue
- Hypertension
- Published
- 2009-09
- Volume
- 54
- Issue
- 3
- Pages
- 516-523
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2114792859
- Cited by
- 231
- References
- 14
- FWCI
- 7.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema. https://app.cochat.ai/papers/10.1161/hypertensionaha.109.134197
- The paper
- Brown, N. J., Byiers, S., Carr, D., Maldonado, M., & Warner, B. A. (2009). Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema. Hypertension. https://doi.org/10.1161/hypertensionaha.109.134197
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.